TMEM2 suppresses TLR3-mediated IFN-β/ISG56/CXCL10 expression in BEAS-2B bronchial epithelial cells-Reference-Cited by-同舟云学术

TMEM2 suppresses TLR3-mediated IFN-β/ISG56/CXCL10 expression in BEAS-2B bronchial epithelial cells

Published:2024-03-14 Issue:1 Volume:51 Page:
ISSN:0301-4851
Container-title:Molecular Biology Reports
language:en
Short-container-title:Mol Biol Rep

Author:

Kobori Yuri^ORCID,Tachizaki Mayuki,Imaizumi Tadaatsu,Tanaka Yusuke,Seya Kazuhiko,Miki Yasuo,Kawaguchi Shogo,Matsumiya Tomoh,Tobisawa Yuki,Ohyama Chikara,Tasaka Sadatomo

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s11033-024-09346-3.pdf

Reference32 articles.

1. Kawai T, Akira S (2011) Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity 34(5):637–650. https://doi.org/10.1016/j.immuni.2011.05.006

2. Blasius AL, Beutler B (2010) Intracellular toll-like receptors. Immunity 32(3):305–315. https://doi.org/10.1016/j.immuni.2010.03.012

3. Guillot L, Le Goffic R, Bloch S, Escriou N, Akira S, Chignard M, Si-Tahar M (2005) Involvement of toll-like receptor 3 in the immune response of lung epithelial cells to double-stranded RNA and influenza a virus. J Biol Chem 280(7):5571–5580. https://doi.org/10.1074/jbc.m410592200

4. Doyle SE, Vaidya SA, O’Connell R, Dadgostar H, Dempsey PW, Wu T-T, Rao G, Sun R, Haberland ME, Modlin RL, Cheng G (2002) IRF3 mediates a TLR3/TLR4-specific antiviral gene program. Immunity 17(3):251–263. https://doi.org/10.1016/s1074-7613(02)00390-4

5. Yamamoto M, Sato S, Hemmi H, Hoshino K, Kaisho T, Sanjo H, Takeuchi O, Sugiyama M, Okabe M, Takeda K, Akira S (2003) Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. Science 301(5633):640–643. https://doi.org/10.1126/science.1087262

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. In-silico analysis of TMEM2 as a pancreatic adenocarcinoma and cancer-associated fibroblast biomarker, and functional characterization of NSC777201, for targeted drug development;American Journal of Cancer Research;2024